Abstract 126: Efficacy of octreotide Long Acting Repeatable (LAR) in acromegaly: An experience from a tertiary care center of eastern India

Background: Octreotide long-acting release (LAR) is a medication used for acromegaly thatcan normalize insulin-like growth factor-1 (IGF-1) and serum growth hormone (GH) levels, leadto tumor shrinkage, and improvement of symptoms of disease activity. Previous studies arelacking regarding the long-term efficacy in Indian populations. This retrospective study aimed toevaluate its effectiveness in a cohort of Indian patients with acromegaly. Methods: Overall, 26 patients with acromegaly, who received regular octreotide LARtreatment at least 6 times at SSKM & IPGMER Hospital between 2017 and 2022, were included. Epidemiological characteristics, acromegaly activity, IGF-1 levels, MRI data pre and posttreatment were collected for investigation. Results: The study registered 26 patients, including 10 men (38%) with a mean age 33 years. After octreotide LAR therapy, 82% of the patients achieved IGF-1 control (